SCHEMBL2431530

SCHEMBL2431530

CC1COC(Cn2nc[nH]c2=S)(c2ccc(Oc3ccc(Cl)cc3)cc2Cl)O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 20/20 0.42
THRB P10828 1/20 0.42
NR1I2 O75469 2/20 0.36
LMNA P02545 2/20 0.36
HSP90AA1 P07900 2/20 0.36
CHRM2 P08172 2/20 0.36
ADRA2A P08913 2/20 0.36
TSHR P16473 2/20 0.36
ADRA2B P18089 2/20 0.36
SLC6A2 P23975 2/20 0.36
HTR2A P28223 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
KCNH2 Q12809 2/20 0.36
CYP51A1 Q16850 2/20 0.36
FYN P06241 1/20 0.36
PGR P06401 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1279572 0.81 CYP3A4 (0.44) CYP3A4THRBNR1I2LMNAHSP90AA1
SCHEMBL30611136 0.81 CYP3A4 (0.47) CYP3A4THRBNR1I2LMNAHSP90AA1
SCHEMBL21887073 0.81 CYP3A4 (0.47) CYP3A4THRBNR1I2LMNAHSP90AA1
Difenoconazole SCHEMBL15932554 0.79 CYP3A4 (0.68) CYP3A4THRBNR1I2LMNAHSP90AA1
Difenoconazole SCHEMBL20654517 0.79 CYP3A4 (0.68) CYP3A4THRBNR1I2LMNAHSP90AA1
Difenoconazole SCHEMBL22126 0.79 CYP3A4 (0.68) CYP3A4THRBNR1I2LMNAHSP90AA1
Difenoconazole SCHEMBL3015472 0.79 CYP3A4 (0.68) CYP3A4THRBNR1I2LMNAHSP90AA1
Difenoconazole SCHEMBL15932941 0.79 CYP3A4 (0.68) CYP3A4THRBNR1I2LMNAHSP90AA1
Difenoconazole SCHEMBL22125 0.79 CYP3A4 (0.68) CYP3A4THRBNR1I2LMNAHSP90AA1
Difenoconazole SCHEMBL29391271 0.79 CYP3A4 (0.68) CYP3A4THRBNR1I2LMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2547687-B1 A PROCESS USING GRIGNARD REAGENTS BASF SE (DE) 2015-07-01 EP disclosed
US-8729272-B2 Process using grignard reagents BASF SE (DE) 2014-05-20 US disclosed
EP-2547687-A1 A PROCESS USING GRIGNARD REAGENTS BASF SE (DE) 2013-01-23 EP disclosed
US-20130005985-A1 Process Using Grignard Reagents BASF SE (DE) 2013-01-03 US disclosed
WO-2011113820-A1 A PROCESS USING GRIGNARD REAGENTS BASF SE (DE) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005985-A1 Process Using Grignard Reagents GTF3C4, GRIA4, GRK4 CYP3A4 55/4885THRB 587/4885NR1I2 2260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.